CDMO Almac adding 100 employees to its North Carolina site

CDMO Almac is adding a fourth building to its site in Durham, North Carolina. (Almac)

U.K.-based CDMO Almac is adding to its U.S. operations with a new building at its site in North Carolina where it says it will house 100 new employees.

The company Wednesday said the 24,000-square-foot office building will be its fourth at the Durham, North Carolina, site. The company declined to say precisely how much it is investing, but a spokesperson said in an email that it will be “multi millions” of dollars. The company will add the 100 workers over the next three years.

Almac last invested in the North Carolina clinical and diagnostic services operations in 2016 when it put $5.2 million into the facilities.  

RELATED: CDMO Almac continues its expansion momentum with lab deal

The Northern Ireland-based company has been steadily expanding its global footprint. Also in 2016, it laid out plans for additions to several facilities, including a $25 million (£20 million) investment to expand its 240,000-square-foot offices at its U.S. headquarters in Souderton, Pennsylvania, and to lease a 26,000-square-foot office space in nearby Lansdale. Those projects were slated to add 312 jobs in the U.S.

Last year, it acquired BioClin Laboratories based in Athlone, Ireland, just two hours away from Almac Group’s headquarters in Craigavon. Almac said BioClin’s expertise and 14,000-square-foot facility significantly increased its analytical capacity and capabilities. It had already invested $6.3 million (£5 million) to build an additional laboratory and office facility at its headquarters.

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.